Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Mar 21, 2019 • 9:00 AM EDT
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Mar 12, 2019 • 4:01 PM EDT
Ligand to Participate in Four Upcoming Investor Conferences
Mar 12, 2019 • 10:00 AM EDT
Ligand Provides Highlights from Today’s Analyst Day Event
Mar 18, 2019 • 4:30pm EDT
Laguna Niguel, California
See all events
Mar 13, 2019 • 9:00am EDT
Mar 12, 2019 • 10:00am - 12:00pm EDT
New York City
Apr 9, 2019
May 29, 2019
$SAGE announces FDA approval of ZULRESSO (brexanolone) injection, the first and only treatment specifically indicat… https://t.co/kSskvuue6c
Viking Therapeutics announces that initiation of Phase 2b Study of VK2809 in biopsy-confirmed NASH is planned for 2… https://t.co/Kb1B01Bp5A
Viking Therapeutics announces that additional VK2809 Phase 2 data to be presented at #EASL19, and that results demo… https://t.co/6YUH2GSo9p